Eyenovia is looking to raise up to $35 million in an initial public offering, according to recent filings. The company plans to use the funds to support trials of its device, which is designed to deliver small doses of drugs to the eye.
The New York-based company uses a piezo-electric dispensation technology to deliver microdoses of drugs topically to the eye. The device tracks patient compliance and is designed to help avoid the adverse events linked to treating eye diseases, which Eyenovia hypothesizes are due to the large volume of drug delivered by traditional eye droppers.
Get the full story at our sister site, Drug Delivery Business News.
The post Eyenovia looks to $35m IPO for ocular drug-delivery tech appeared first on MassDevice.